Clinical Trial Detail

NCT ID NCT03992456
Title Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Academic and Community Cancer Research United
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Panitumumab

Regorafenib

Trifluridine-tipiracil hydrochloride

Age Groups: senior adult

Additional content available in CKB BOOST